Importantly, we recently showed that blocking the PD-1/PD-L1 signaling pathway markedly improved anti-CD38 antibody-mediated anti-tumor activity in an anti-CD38 antibody naïve MM mouse model [15]. This evidence concerns the gene CD38 and neoplasm.